Suppr超能文献

长新冠和心脏:心脏线粒体是缺失的一环吗?

Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link?

机构信息

Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.

出版信息

Antioxid Redox Signal. 2023 Mar;38(7-9):599-618. doi: 10.1089/ars.2022.0126. Epub 2022 Dec 28.

Abstract

Although corona virus disease 2019 (COVID-19) has now gradually been categorized as an endemic, the long-term effect of COVID-19 in causing multiorgan disorders, including a perturbed cardiovascular system, is beginning to gain attention. Nonetheless, the underlying mechanism triggering post-COVID-19 cardiovascular dysfunction remains enigmatic. Are cardiac mitochondria the key to mediating cardiac dysfunction post-severe acute respiratory syndrome coronavirus 2 (post-SARS-CoV-2) infection? Cardiovascular complications post-SARS-CoV-2 infection include myocarditis, myocardial injury, microvascular injury, pericarditis, acute coronary syndrome, and arrhythmias (fast or slow). Different types of myocardial damage or reduced heart function can occur after a lung infection or lung injury. Myocardial/coronary injury or decreased cardiac function is directly associated with increased mortality after hospital discharge in patients with COVID-19. The incidence of adverse cardiovascular events increases even in recovered COVID-19 patients. Disrupted cardiac mitochondria postinfection have been postulated to lead to cardiovascular dysfunction in the COVID-19 patients. Further studies are crucial to unravel the association between SARS-CoV-2 infection, mitochondrial dysfunction, and ensuing cardiovascular disorders (CVD). The relationship between COVID-19 and myocardial injury or cardiovascular dysfunction has not been elucidated. In particular, the role of the cardiac mitochondria in this association remains to be determined. Elucidating the cause of cardiac mitochondrial dysfunction post-SARS-CoV-2 infection may allow a deeper understanding of long COVID-19 and resulting CVD, thus providing a potential therapeutic target. 38, 599-618.

摘要

虽然 2019 年冠状病毒病 (COVID-19) 现已逐渐归类为地方病,但 COVID-19 长期导致多器官紊乱的影响,包括心血管系统失调,开始引起关注。然而,引发 COVID-19 后心血管功能障碍的潜在机制仍然是个谜。心脏线粒体是否是介导严重急性呼吸系统综合征冠状病毒 2 (post-SARS-CoV-2)感染后心脏功能障碍的关键?SARS-CoV-2 感染后的心血管并发症包括心肌炎、心肌损伤、微血管损伤、心包炎、急性冠状动脉综合征和心律失常(快或慢)。肺部感染或肺损伤后可能会发生不同类型的心肌损伤或心脏功能降低。心肌/冠状动脉损伤或心功能降低与 COVID-19 患者出院后死亡率增加直接相关。即使在 COVID-19 已康复的患者中,不良心血管事件的发生率也会增加。感染后心脏线粒体的破坏被推测会导致 COVID-19 患者的心血管功能障碍。进一步的研究对于揭示 SARS-CoV-2 感染、线粒体功能障碍和随后的心血管疾病 (CVD) 之间的关联至关重要。COVID-19 与心肌损伤或心血管功能障碍之间的关系尚未阐明。特别是,心脏线粒体在这种关联中的作用仍有待确定。阐明 SARS-CoV-2 感染后心脏线粒体功能障碍的原因可能有助于更深入地了解长 COVID-19 和由此产生的 CVD,从而提供潜在的治疗靶点。38, 599-618。

相似文献

1
Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link?长新冠和心脏:心脏线粒体是缺失的一环吗?
Antioxid Redox Signal. 2023 Mar;38(7-9):599-618. doi: 10.1089/ars.2022.0126. Epub 2022 Dec 28.
3
COVID-19 and its long-term impact on the cardiovascular system.新型冠状病毒肺炎及其对心血管系统的长期影响。
Expert Rev Cardiovasc Ther. 2023 Mar;21(3):211-218. doi: 10.1080/14779072.2023.2184800. Epub 2023 Mar 6.
4
Cell-Specific Mechanisms in the Heart of COVID-19 Patients.新型冠状病毒肺炎患者心脏中的细胞特异性机制。
Circ Res. 2023 May 12;132(10):1290-1301. doi: 10.1161/CIRCRESAHA.123.321876. Epub 2023 May 11.
5
Cardiovascular effects of COVID-19 in children.儿童 COVID-19 的心血管影响。
Ann Acad Med Singap. 2023 Oct 30;52(10):533-541. doi: 10.47102/annals-acadmedsg.202386.
7
Sex differences in the cardiac stress response following SARS-CoV-2 infection of ferrets.在雪貂感染 SARS-CoV-2 后,心脏应激反应的性别差异。
Am J Physiol Heart Circ Physiol. 2023 Nov 1;325(5):H1153-H1167. doi: 10.1152/ajpheart.00101.2023. Epub 2023 Sep 22.
9
Cardiac Manifestations of Post-Acute COVID-19 Infection.急性 COVID-19 感染后心脏表现。
Curr Cardiol Rep. 2022 Dec;24(12):1775-1783. doi: 10.1007/s11886-022-01793-3. Epub 2022 Nov 2.
10
Myocardial injury and COVID-19: Possible mechanisms.心肌损伤与 COVID-19:可能的机制。
Life Sci. 2020 Jul 15;253:117723. doi: 10.1016/j.lfs.2020.117723. Epub 2020 Apr 28.

引用本文的文献

10
Mechanisms of long COVID: An updated review.长新冠的发病机制:最新综述
Chin Med J Pulm Crit Care Med. 2023 Dec 6;1(4):231-240. doi: 10.1016/j.pccm.2023.10.003. eCollection 2023 Dec.

本文引用的文献

6
Remdesivir; molecular and functional measures of mitochondrial safety.瑞德西韦;线粒体安全性的分子和功能测量。
Toxicol Appl Pharmacol. 2021 Dec 15;433:115783. doi: 10.1016/j.taap.2021.115783. Epub 2021 Nov 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验